Breast cancer affects people across ages and countries, and risk can vary widely due to genetics, exposures, and family history. In the U.S., it accounts for about 30% of new cancer cases in women, while factors like BRCA1 mutations, first-degree relatives, hormone therapy, and obesity can raise risk. This page also covers how screening tools perform and how outcomes differ by tumor stage and treatment choices.
Key Takeaways
- Mammography screening reduces breast cancer mortality by 20-40% in women 40-74
- In U.S., 61.3% of women 50-74 had mammogram in past 2 years (2019)
- Digital breast tomosynthesis (3D mammogram) reduces recall rate by 15%
- In 2023, an estimated 297,790 new cases of invasive breast cancer will be diagnosed in women in the U.S.
- Breast cancer accounts for about 30% of all new cancer cases in women in the U.S.
- Globally, breast cancer was the most commonly diagnosed cancer in 2020 with 2.3 million new cases
- U.S. breast cancer death rate 19.2 per 100,000 women per year (2016–2020)
- From 2012–2021, breast cancer mortality declined 1.1% annually in U.S.
- Globally, 670,000 breast cancer deaths in 2022
- Women with a first-degree relative with breast cancer have 2-fold increased risk
- BRCA1 mutation carriers have 55-72% lifetime risk of breast cancer
- Postmenopausal hormone therapy (estrogen + progestin) increases risk by 24% after 5 years use
- 5-year survival for localized breast cancer is 99.3%
- Lumpectomy + radiation survival equals mastectomy at 95% 10-year
- Neoadjuvant chemotherapy downsizes 70% of tumors to allow breast conservation
Regular screening and modern treatments save lives, helping reduce breast cancer mortality and recurrence.
Related reading
01 · Category
Diagnosis And Detection30 stats
01
Mammography screening reduces breast cancer mortality by 20-40% in women 40-74
02
In U.S., 61.3% of women 50-74 had mammogram in past 2 years (2019)
03
Digital breast tomosynthesis (3D mammogram) reduces recall rate by 15%
04
MRI screening sensitivity 90% vs 72% for mammography in high-risk women
05
Breast ultrasound detects 94% of cancers missed by mammography
06
In 2020, 42% of U.S. women 40+ had mammogram in past year
07
Elastography improves specificity of ultrasound by 20-30%
08
Contrast-enhanced mammography sensitivity 93% for invasive cancer
09
Molecular breast imaging (MBI) sensitivity 90% in dense breasts
10
Automated breast ultrasound (ABUS) detects 2 additional cancers per 1,000 women
11
Digital mammography false-positive rate 10% per screening
12
Breast self-exam detects 20% of cancers but has high false-positive rate
13
AI algorithms improve mammogram sensitivity by 9.4%
14
85% of palpable breast masses are benign
15
Core needle biopsy diagnostic accuracy 97%
16
Stereotactic biopsy success rate 98% for non-palpable lesions
17
Sentinel lymph node biopsy identifies metastases in 30% of early-stage cases
18
PET/CT staging accuracy 92% for axillary nodes
19
Ductal lavage cytology sensitivity 20-50% for high-grade DCIS
20
Thermography has sensitivity <50%, not recommended
21
Oncotype DX score predicts recurrence risk in ER+ node-negative cancer
22
MammaPrint assay stratifies risk in 70-gene signature
23
Prosigna PAM50 test identifies luminal A (low risk) vs B (high risk)
24
21-gene recurrence score <18 low risk, 5% 10-yr distant recurrence
25
Blue dye + radioisotope SLNB detection rate 97%
26
MRI detects additional 13% cancers preoperatively
27
Ductoscopy visualizes 85% of intraductal lesions
28
Liquid biopsy ctDNA detects early recurrence with 90% sensitivity
29
80% of breast cancers are ER-positive
30
HER2-positive tumors 15-20% of cases, tested by IHC/FISH
Interpretation
Diagnosis And Detection Interpretation
For the diagnosis and detection angle, the data show that screening methods meaningfully improve outcomes, with mammography screening cutting breast cancer mortality by 20 to 40% in women ages 40 to 74 and MRI reaching 90% sensitivity versus 72% for mammography in high risk women.
02 · Category
Incidence And Prevalence30 stats
01
In 2023, an estimated 297,790 new cases of invasive breast cancer will be diagnosed in women in the U.S.
02
Breast cancer accounts for about 30% of all new cancer cases in women in the U.S.
03
Globally, breast cancer was the most commonly diagnosed cancer in 2020 with 2.3 million new cases
04
In the U.S., about 1 in 8 women (12.5%) will develop invasive breast cancer in their lifetime
05
From 2017–2021, the median age at breast cancer diagnosis was 62 years
06
In 2022, breast cancer incidence rates were 130.8 per 100,000 women per year based on 2016–2020 cases
07
Non-Hispanic White women have the highest breast cancer incidence rates at 133.4 per 100,000
08
In Europe, age-standardized incidence rate of breast cancer is 89.8 per 100,000 women
09
In low- and middle-income countries, breast cancer incidence has increased by over 20% since 2008
10
U.S. breast cancer prevalence is 3,148,100 women living with the disease as of 2022
11
Invasive breast cancer in situ incidence rate is 30.4 per 100,000 women per year (2016–2020)
12
Among U.S. adolescents and young adults (15–39 years), breast cancer accounts for 5.6% of female cancer cases
13
In 2020, India reported 208,953 new breast cancer cases, highest in Asia
14
Breast cancer incidence in U.S. men is 1.5 per 100,000
15
From 2012–2021, U.S. breast cancer incidence increased by 0.3% annually
16
In Australia, breast cancer incidence rate is 94.5 per 100,000 women
17
U.S. Black women have incidence rate of 126.5 per 100,000 (2016–2020)
18
Globally, 685,000 breast cancer deaths occurred in 2020
19
In the UK, 55,500 new breast cancer cases annually (2017–2019 average)
20
U.S. Asian/Pacific Islander women incidence: 105.0 per 100,000
21
Brazil reported 73,610 new cases in 2020
22
Lifetime risk of developing breast cancer is 13.1% for U.S. women
23
In Japan, incidence rate is 86.0 per 100,000 women
24
U.S. Hispanic women incidence: 93.1 per 100,000 (2016–2020)
25
China had 416,366 new cases in 2020
26
In Canada, 28,600 new cases expected in 2023
27
U.S. American Indian/Alaska Native incidence: 112.5 per 100,000
28
France incidence rate: 105.3 per 100,000 women
29
In 2021, 2,671,000 women in U.S. living with metastatic breast cancer history
30
Global age-standardized incidence rate for breast cancer is 47.8 per 100,000 women
Interpretation
Incidence And Prevalence Interpretation
Within the incidence and prevalence angle, the data show breast cancer is both common and persistent, with about 297,790 new invasive cases expected in the U.S. in 2023 and roughly 1 in 8 women, or 12.5%, developing it over their lifetime.
03 · Category
Mortality And Prevention28 stats
01
U.S. breast cancer death rate 19.2 per 100,000 women per year (2016–2020)
02
From 2012–2021, breast cancer mortality declined 1.1% annually in U.S.
03
Globally, 670,000 breast cancer deaths in 2022
04
Black women have 40% higher breast cancer mortality than White women
05
5-year relative survival for distant stage breast cancer is 31.9%
06
In low-income countries, 5-year survival <40% vs >80% high-income
07
Screening mammography averted 522,000 deaths in U.S. 1989-2012
08
Tamoxifen prophylaxis reduces risk 50% in high-risk women
09
Raloxifene reduces risk 38% with fewer side effects than tamoxifen
10
Risk-reducing salpingo-oophorectomy reduces breast cancer risk 50% in BRCA carriers
11
Bilateral mastectomy reduces risk >90% in BRCA1/2 carriers
12
5% weight loss reduces postmenopausal risk by 12%
13
Limiting alcohol to <1 drink/day reduces risk 10%
14
150 min moderate exercise/week reduces risk 20%
15
Breastfeeding for 12 months cumulatively reduces risk 26%
16
Aspirin use reduces risk 9% with long-term use
17
Statins may reduce risk 20-30% in some studies
18
Vitamin D levels >40 ng/ml associated with 30% lower risk
19
Soy isoflavones safe, no increased risk in Asian populations
20
Smoking cessation before 40 reduces risk almost to never-smoker level
21
Healthy diet (high fruit/veg, low fat) reduces risk 10-20%
22
Early screening (40-44) reduces mortality 15% in that group
23
HPV vaccine indirect? No, but lifestyle prevention key, wait adjust: BRCA testing identifies 10% actionable high-risk
24
Population screening reduces mortality 20% in Europe
25
Post-diagnosis exercise reduces recurrence 30-40%
26
Adherence to endocrine therapy >80% improves survival 20%
27
Global breast cancer mortality projected to rise 30% by 2040 without action
28
U.S. breast cancer deaths: 42,250 expected in 2023
Interpretation
Mortality And Prevention Interpretation
Breast cancer mortality is improving in the U.S. with a 1.1% annual decline from 2012 to 2021, yet major prevention and equity gaps remain, since globally 670,000 people died in 2022 and Black women face 40% higher mortality than White women.
More related reading
04 · Category
Risk Factors And Causes30 stats
01
Women with a first-degree relative with breast cancer have 2-fold increased risk
02
BRCA1 mutation carriers have 55-72% lifetime risk of breast cancer
03
Postmenopausal hormone therapy (estrogen + progestin) increases risk by 24% after 5 years use
04
Obesity increases postmenopausal breast cancer risk by 20-40%
05
Alcohol consumption: risk increases 7-10% per 10g daily intake
06
Dense breast tissue increases risk 4-6 times compared to fatty breasts
07
Nulliparity (never giving birth) increases risk by 30%
08
Late age at first full-term pregnancy (>30 years) increases risk by 20-30%
09
Oral contraceptive use increases risk by 20% currently, drops after discontinuation
10
Radiation exposure before age 30 doubles breast cancer risk
11
Physical inactivity increases risk by 20-30%
12
BRCA2 mutation lifetime risk: 45-69%
13
Previous breast biopsy showing hyperplasia increases risk 1.5-2 times
14
Smoking: long-term smokers have 9% higher risk
15
Early menarche (<12 years) increases risk by 20%
16
Late menopause (>55 years) increases risk by 35%
17
DES exposure in utero increases risk 1.5 times
18
Shift work with circadian disruption increases risk by 20%
19
High breast density (heterogeneously dense) 4x risk, extremely dense 6x
20
Family history accounts for 5-10% of breast cancers
21
TP53 mutation risk up to 90% lifetime
22
Not breastfeeding increases risk by 4% per year of no breastfeeding
23
Ovarian cancer history increases breast cancer risk 2-3 times
24
Ashkenazi Jewish women have 2x risk for BRCA mutations
25
Hormone replacement therapy (estrogen only) 15% increased risk after 5 years
26
Diabetes increases risk by 20%
27
15-25% of breast cancers overexpress HER2
28
ATM gene mutation increases risk 2-3 fold
29
CHEK2 mutation carriers 2-4x risk
30
PALB2 mutation risk similar to BRCA2 (40-60%)
Interpretation
Risk Factors And Causes Interpretation
Across the key risk factors behind breast cancer, inherited predisposition and hormone related exposures stand out, with first degree relatives doubling risk and BRCA1 mutation carriers facing a 55 to 72% lifetime risk, while postmenopausal estrogen plus progestin use raises risk by about 24% after five years.
05 · Category
Treatment And Survival27 stats
01
5-year survival for localized breast cancer is 99.3%
02
Lumpectomy + radiation survival equals mastectomy at 95% 10-year
03
Neoadjuvant chemotherapy downsizes 70% of tumors to allow breast conservation
04
Tamoxifen reduces recurrence by 50% in ER+ premenopausal women
05
Trastuzumab improves DFS by 46% in HER2+ early breast cancer
06
Aromatase inhibitors reduce recurrence 40% vs tamoxifen in postmenopausal
07
Radiation after lumpectomy reduces local recurrence from 30% to 8%
08
CDK4/6 inhibitors + endocrine therapy improve PFS to 28 months in metastatic ER+
09
Anthracycline-taxane chemo improves DFS by 17% in node-positive
10
Accelerated partial breast irradiation 5-yr IBTR 2.7% vs 3.6% whole breast
11
Dual HER2 blockade (pertuzumab + trastuzumab) DFS 86% at 3 years
12
Abemaciclib adjuvant reduces recurrence by 25% in high-risk HR+
13
Hypofractionated radiation (40Gy/15fx) equivalent to standard 50Gy/25fx
14
Ovarian suppression + AI improves DFS 21% in premenopausal high-risk
15
Capecitabine improves OS by 16% in triple-negative metastatic
16
Pembrolizumab + chemo improves pCR 65% in TNBC neoadjuvant
17
10-year survival for stage I breast cancer 89%
18
Bisphosphonates reduce recurrence 18% in postmenopausal ER+
19
Intraoperative radiation single dose IBTR 3.3% at 5 years
20
Ribociclib + endocrine PFS 25.3 months in advanced HR+
21
Olaparib adjuvant improves 3-yr DFS to 85.9% in BRCA+ early
22
Dose-dense chemo improves DFS 17% in node-positive
23
Everolimus + exemestane PFS 7.8 vs 3.2 months in advanced
24
Sacituzumab govitecan OS 12.1 months in pretreated metastatic TNBC
25
Tucatinib + trastuzumab/capecitabine PFS 7.8 months HER2+ metastatic
26
Niraparib + abiraterone no benefit in BRCA- breast
27
DESTINY-Breast03 T-DXd PFS not reached vs 6.8 months
Interpretation
Treatment And Survival Interpretation
In Treatment and Survival, modern therapies are substantially improving outcomes, with 5-year survival reaching 99.3% for localized disease and targeted strategies like trastuzumab increasing disease-free survival by 46% in HER2+ early breast cancer.
report visual · Breakdown
Breast Cancer Diagnosis & Detection: Screening & Imaging Performance
Mammography screening and advanced imaging improve detection, while recall reduction and sensitivity gains highlight better diagnostic accuracy.
15%
Digital breast tomosynthesis (3D mammogram) reduces recall rate by 15%
85%
85% of palpable breast masses are benign
report visual · Key figures
Breast cancer incidence is rising in the U.S.
U.S. breast cancer incidence increased steadily over time.
0.3%
From 2012–2021, U.S. breast cancer incidence increased by 0.3% annually
297,790
In 2023, an estimated 297,790 new cases of invasive breast cancer will be diagnosed in women in the U.S.
30%
Breast cancer accounts for about 30% of all new cancer cases in women in the U.S.
report visual · Key figures
Breast cancer mortality has been declining in the U.S., but future risk could rise globally without prevention
U.S. mortality declined over time, while global projections indicate potential increases without action.
1.1%
From 2012–2021, breast cancer mortality declined 1.1% annually in U.S.
100,000
U.S. breast cancer death rate 19.2 per 100,000 women per year (2016–2020)
30%
Global breast cancer mortality projected to rise 30% by 2040 without action
42,250
U.S. breast cancer deaths: 42,250 expected in 2023
report visual · Key figures
Key Breast Cancer Risk Factors
Selected major genetic and lifestyle risk factors that increase breast cancer risk or lifetime risk.
2
Women with a first-degree relative with breast cancer have 2-fold increased risk
-72%
BRCA1 mutation carriers have 55-72% lifetime risk of breast cancer
24%
Postmenopausal hormone therapy (estrogen + progestin) increases risk by 24% after 5 years use
4
Dense breast tissue increases risk 4-6 times compared to fatty breasts
30%
Nulliparity (never giving birth) increases risk by 30%
35%
Late menopause (>55 years) increases risk by 35%
report visual · Key figures
Treatment impact on survival and recurrence
Key survival outcomes and treatment-associated risk reductions illustrate how different therapies affect long-term outcomes in breast cancer.
99.3%
5-year survival for localized breast cancer is 99.3%
95%
Lumpectomy + radiation survival equals mastectomy at 95% 10-year
30%
Radiation after lumpectomy reduces local recurrence from 30% to 8%
50%
Tamoxifen reduces recurrence by 50% in ER+ premenopausal women
46%
Trastuzumab improves DFS by 46% in HER2+ early breast cancer
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Julian Richter. (2026, February 13). Breast Cancer Statistics. Gitnux. https://gitnux.org/breast-cancer-statistics
MLA
Julian Richter. "Breast Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/breast-cancer-statistics.
Chicago
Julian Richter. 2026. "Breast Cancer Statistics." Gitnux. https://gitnux.org/breast-cancer-statistics.
Sources & references
37 datasets cited across this report · attribution is report-level